ArticleApplied psychophysiology and biofeedback2025
Basal ganglia as an fMRI motor neurofeedback target in Parkinson's disease.
Article in Applied psychophysiology and biofeedback, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Technical considerations of functional MRI in deep brain stimulation: recent advances and future perspectives.NeuroImage · 2026Review
- Neurofeedback as an emerging rehabilitation strategy for Parkinson's disease: a narrative review.Frontiers in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor impairments. While pharmacological treatments offer symptom alleviation, their long-term effectiveness is insufficient. Deep Brain Stimulation (DBS) is a neurosurgical treatment that targets brain pathways to alleviate motor symptoms in PD. It is a highly invasive procedure and carries associated risks. This prompts investigation of non-invasive alternatives, such as real-time functional Magnetic Resonance Imaging (rt-fMRI) neurofeedback (NF). This work investigates the feasibility of using the basal ganglia, more specifically the putamen, a key structure in the motor network, as a potential NF target region. Two rt-fMRI studies were conducted: (i) Twelve healthy individuals participated in a single-blind, crossover study involving one MRI session targeting the putamen and the supplementary motor area (SMA) in separate runs. (ii) Twelve PD patients followed the same protocol but with three MRI sessions. We investigated whether participants could learn to voluntarily control brain activity through NF training. The PD patients successfully recruited the putamen during NF-reinforced motor imagery, which was also found at trend level in the healthy participants. We found no learning effect and no difference in putamen activation when it was directly targeted versus when the target signals came from the SMA. Overall, widespread cortical and subcortical areas involved in motor control were activated during neurofeedback. This study demonstrates for the first time that PD patients can modulate putamen activity through NF training, supporting its potential as a non-invasive neuromodulation target. This opens opportunities for integrating invasive and non-invasive neuromodulation for PD treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.